These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1593353)

  • 21. Marked pleural effusion after i.v. immunoglobulin therapy for Kawasaki disease.
    Koizumi K; Hoshiai M; Toda T; Nakane T; Sugita K
    Pediatr Int; 2018 Mar; 60(3):307-308. PubMed ID: 29480538
    [No Abstract]   [Full Text] [Related]  

  • 22. The Complexities of the Diagnosis and Management of Kawasaki Disease.
    Rowley AH
    Infect Dis Clin North Am; 2015 Sep; 29(3):525-37. PubMed ID: 26154665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Kawasaki disease.
    Nakashima L; Edwards DL
    Clin Pharm; 1990 Oct; 9(10):755-62. PubMed ID: 2242655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The treatment of Kawasaki syndrome with intravenous gamma globulin.
    Newburger JW; Takahashi M; Burns JC; Beiser AS; Chung KJ; Duffy CE; Glode MP; Mason WH; Reddy V; Sanders SP
    N Engl J Med; 1986 Aug; 315(6):341-7. PubMed ID: 2426590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical manifestations and effects of IVGG in patients with Kawasaki disease].
    Hwang KP; Wu JR; Huang LY; Liou CC; Huang TY
    Kaohsiung J Med Sci; 1996 Mar; 12(3):159-66. PubMed ID: 8709183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin.
    Leung DY
    Clin Exp Immunol; 1996 May; 104 Suppl 1():49-54. PubMed ID: 8625544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preventing Long-Term Cardiac Damage in Pediatric Patients With Kawasaki Disease.
    Williams K
    J Pediatr Health Care; 2017; 31(2):196-202. PubMed ID: 27592169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous immune globulin use in children. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.
    CMAJ; 1992 Jan; 146(2):121-4. PubMed ID: 1735037
    [No Abstract]   [Full Text] [Related]  

  • 29. Management of Kawasaki disease in resource-limited settings.
    Singh S; Newburger JW; Kuijpers T; Burgner D
    Pediatr Infect Dis J; 2015 Jan; 34(1):94-6. PubMed ID: 25741801
    [No Abstract]   [Full Text] [Related]  

  • 30. Safeguarding immune globulin recipients against hemolysis: what do we know and where do we go?
    Scott DE; Epstein JS
    Transfusion; 2015 Jul; 55 Suppl 2():S122-6. PubMed ID: 26174890
    [No Abstract]   [Full Text] [Related]  

  • 31. Kawasaki disease.
    Huang TY
    Acta Paediatr Taiwan; 2004; 45(1):6-7. PubMed ID: 15264698
    [No Abstract]   [Full Text] [Related]  

  • 32. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura.
    Gaines AR
    Blood; 2005 Sep; 106(5):1532-7. PubMed ID: 15878975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Yersinia pseudotuberculosis type 4a infection meeting the diagnostic criteria for Kawasaki disease complicated by disseminated intravascular coagulation].
    Usui D; Ishii Y; Akaike H; Isumi H; Komura H; Kawasaki K; Ouchi K
    Kansenshogaku Zasshi; 2005 Nov; 79(11):895-9. PubMed ID: 16366361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Demonstration of a fatal hemolytic transfusion reaction using immunoperoxidase techniques.
    Cumberland GD; Titford M; Riddick L
    Am J Forensic Med Pathol; 1991 Sep; 12(3):250-1. PubMed ID: 1750399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
    Mori M; Imagawa T; Yasui K; Kanaya A; Yokota S
    J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous gamma globulin therapy in Kawasaki disease--trial of low dose gamma globulin.
    Okuni M; Harada K; Yamaguchi H; Yanagawa H; Sonobe T; Kawasaki T
    Prog Clin Biol Res; 1987; 250():433-9. PubMed ID: 3321083
    [No Abstract]   [Full Text] [Related]  

  • 37. A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin-mediated hemolysis.
    Pendergrast J; Armali C; Callum J; Cserti-Gazdewich C; Jiwajee A; Lieberman L; Lau W; Lin Y; Parmar N; Pavenski K; Riden LS; Shehata N; Willie-Ramharack K; Tomlinson G; Tong TN; Binnington B; Branch DR;
    Transfusion; 2021 Apr; 61(4):1053-1063. PubMed ID: 33433931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
    Qin LJ; Wang HW; Hu XF; Liu QJ; Shi H; Wei YX; Chen QJ; Cheng PX
    Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease.
    Jibiki T; Terai M; Kurosaki T; Nakajima H; Suzuki K; Inomata H; Terashima I; Honda T; Yasukawa K; Hamada H; Kohno Y
    Eur J Pediatr; 2004 Apr; 163(4-5):229-33. PubMed ID: 14963702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kawasaki disease with DIC as a complication.
    Parvathy VK; Manuel AD; Criton S; Rajesh G
    Indian J Pediatr; 2007 Nov; 74(11):1049. PubMed ID: 18057693
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.